{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:28:49Z","timestamp":1791264529932,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T00:00:00Z","timestamp":1423699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The main purpose of this study was to evaluate the risk of major malformations after aripiprazole exposure during the embryonic period. The secondary purposes were to assess the risk of miscarriage, prematurity, fetal growth retardation and maternal complications and to describe possible neonatal adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cohort study using data prospectively collected by the French Pharmacovigilance Centres participating to the Terappel program and the Centre de R\u00e9f\u00e9rence sur les Agents T\u00e9ratog\u00e8nes between 2004 and 2011. The exposed group consisted of pregnant women exposed to aripiprazole during embryogenesis, and the unexposed group consisted of pregnant women without exposure or exposed to non\u2010teratogenic agents. Two unexposed patients, matched for age and gestational age at call, were randomly selected for each exposed patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty\u2010six patients were included in the exposed group and 172 in the unexposed group. Exposure to aripiprazole was not significantly associated with an increased rate of major malformations (OR 2.30, 95%CI 0.32\u201316.7) or miscarriage (1.66, 0.63\u20134.38) or gestational diabetes (1.15, 0.33\u20134.04) compared to non\u2010exposure. The study revealed significantly increased rates of prematurity (OR 2.57, 95%CI 1.06\u20136.27) and fetal growth retardation (2.97, 1.23\u20137.16) in exposed newborns, difficult to interpret because of the short duration of maternal exposure. Two cases of neonatal complications were reported among the 19 newborns exposed to aripiprazole near delivery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study failed to demonstrate a significant association between aripiprazole exposure during the embryonic period and major malformations. More powerful prospective studies are required to clarify the reproductive safety profile of aripiprazole. Copyright \u00a9 2015 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3749","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T10:25:46Z","timestamp":1423823146000},"page":"368-380","source":"Crossref","is-referenced-by-count":54,"title":["Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study"],"prefix":"10.1002","volume":"24","author":[{"given":"Florelle","family":"Bellet","sequence":"first","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance Centre Hospitalo\u2010Universitaire  Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010No\u00eblle","family":"Beyens","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance Centre Hospitalo\u2010Universitaire  Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Bernard","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Beghin","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence sur les Agents T\u00e9ratog\u00e8nes H\u00f4pital Trousseau  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Elefant","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence sur les Agents T\u00e9ratog\u00e8nes H\u00f4pital Trousseau  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Vial","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance Hospices Civils de Lyon  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,12]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Reprotox. Aripiprazole 2013. Available at:http:\/\/www.reprotox.org(accessed October 2013)."},{"key":"e_1_2_7_3_1","first-page":"97","volume-title":"Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk","author":"Briggs GG","year":"2005"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-008-0044-3"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318295fe12"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.reprotox.2013.02.032","article-title":"Is the use of aripiprazole safe during first trimester of pregnancy? [abstract]","volume":"37","author":"Paulus WE","year":"2013","journal-title":"Reprod Toxicol"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094788"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2006.00316.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2007.01.685"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00737-008-0022-9"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d27c7d"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/00048674.2011.566547"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1312591"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0924-9338(13)76693-8","article-title":"The use of aripiprazole during pregnancy: a case report [abstract]","volume":"28","author":"Derganc M","year":"2013","journal-title":"Eur Psychiatry"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000079"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000171"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G507"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318218c400"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318222bc65"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.10012"},{"key":"e_1_2_7_21_1","unstructured":"EUROCAT.Minor anomalies for exclusion 2005. Available at:http:\/\/www.eurocat\u2010network.eu\/content\/EUROCAT\u2010New\u2010List\u2010of\u2010Minor\u2010Anomalies.pdf(accessed July 2012)."},{"key":"e_1_2_7_22_1","unstructured":"AUDIPOG.Estimation de la croissance f\u0153tale et postnatale. Available at:http:\/\/www.audipog.net\/courbes_morpho.php(accessed August 2012)."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-010-1706-8"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b3569"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20144"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002166"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0406"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7099.32"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgyn.2011.11.008"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181d3ca63"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.10.335"},{"key":"e_1_2_7_32_1","unstructured":"FDA Drug Safety Communication.Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns 2011. Available at:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm243903.htm(accessed October 2013)."},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-197"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2013.11.2.80"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3749","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3749","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T03:25:31Z","timestamp":1696476331000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,12]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1002\/pds.3749"],"URL":"https:\/\/doi.org\/10.1002\/pds.3749","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,12]]}}}